HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a $43 price target.
June 14, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics (NASDAQ:ACRS) receives a reiterated Buy rating from HC Wainwright & Co. analyst Raghuram Selvaraju, with a maintained $43 price target.
The reiterated Buy rating and maintained $43 price target by HC Wainwright & Co. analyst Raghuram Selvaraju for Aclaris Therapeutics (NASDAQ:ACRS) indicates a positive outlook for the stock. This news is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100